• Title/Summary/Keyword: 급성 백혈병

Search Result 142, Processing Time 0.035 seconds

Acute Myeloid Leukemia with t(8;21)(q22;q22) (AML1/ETO) in a Patient with Marked Hypocellularity and Low Blasts Count

  • Chun, Sung-Ho;Cho, Hee-Soon;Lee, Chae-Hoon;Kim, Kyung-Dong;Kim, Min-Kyoung;Hyun, Myung-Soo;Jung, Soon-Il
    • Journal of Yeungnam Medical Science
    • /
    • v.24 no.1
    • /
    • pp.85-90
    • /
    • 2007
  • According to the World Health Organization (WHO) classification system, cases with t(8;21)(q22;q22) should be diagnosed as acute myeloid leukemia (AML) even with a blast count of less than 20 percent in blood or bone marrow. It is an uncommon manifestation, moreover hypocellularity is rarely observed in this subtype of leukemia. Here, we report a case of t(8;21) in a patient with marked hypocellularity of less than 5 percent and a blast count of less than 20 percent. This patient responded relatively well to chemotherapy. An allogeneic bone marrow transplantation was performed with good engraftment. This case suggests that hypocellular AML with a t(8;21) has as good a prognosis as hypercellular AML with t(8;21).

  • PDF

A case of atypical hemolytic uremic syndrome as an early manifestation of acute lymphoblastic leukemia (비전형적 용혈성 요독 증후군으로 조기 발현한 급성 림프모구성 백혈병 1예)

  • Han, Dong Kyun;Baek, Hee Jo;Cho, Young Kuk;Kim, Chan Jong;Shin, Myung Geun;Kook, Hoon;Hwang, Tai Ju
    • Clinical and Experimental Pediatrics
    • /
    • v.53 no.2
    • /
    • pp.253-257
    • /
    • 2010
  • Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children younger than 4 years and is characterized by microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. HUS associated with diarrheal prodrome is usually caused by Shiga toxin-producing Escherichia coli O157:H7 or by Shigella dysenteriae, which generally has a better outcome. However, atypical cases show a tendency to relapse with a poorer prognosis. HUS has been reported to be associated with acute lymphoblastic leukemia (ALL) in children. The characteristics and the mechanisms underlying this condition are largely unknown. In this study, we describe the case of an 11-year-old boy in whom the diagnosis of ALL was preceded by the diagnosis of atypical HUS. Thus, patients with atypical HUS should be diagnosed for the possibility of developing ALL.

Effect of Cytarabine, Melphalan, and Total Body Irradiation as Conditioning for Autologous Stem Cell Transplantation for Patients with AML in First Remission (1차 관해된 급성 골수성 백혈병에서 자가 조혈모세포 이식을 위한 Cytarabine, Melphalan, 전신 방사선치료의 효과)

  • Kang Ki Mun;Choi Byung Ock;Chai Gyu Young;Kang Young Nam;Jang Hong Sek;Kim Hee Jae;Min Wo Sung;Kim Chun Choo;Choi Ihl Bohng
    • Radiation Oncology Journal
    • /
    • v.21 no.3
    • /
    • pp.192-198
    • /
    • 2003
  • Purpose: Current results of autologous stem cell transplantation (SCT) suggest that this procedure may prolong disease free survival In patients with acute myeloid leukemia (AML). Autologous SCT is increasingly used as treatment for AML in first remission. The aim of this study was to evaluate the outcome of autologous SCT for patients with AML in first remission treated by autologous SCT using cytarabine, melphalan and total body irradiation (TBI) as the conditioning regimen. Materials and Methods: Between January 1995 and December 1999, 29 patients with AML in first remission underwent autologous SCT. The median age of patients was 33 years (range, 16 to 47). The conditioning regimen consisted of cytarabine ($3.0\;gm/m^2$ for 3 days), melphalan ($100\;gm/m^2$ for 1 day) and TBI (total 1000 cGy in five fractions over 3 days). Results: The median follow up was 40 months with a range of 3 to 58 months. The 4-year cumulative probability of disease free survival was 69.0%, and median survival was 41.5 months. The 4-year relapse rate was 27.6%. The factor Influencing disease free survival and relapse rate was the French-American-British (FAB) classification ($M_3$ group vs. other groups; p=0.048, p=0.043). One patient died from treatment-related toxicity. Conclusion:: Although the small number of patients does not allow us to draw any firm conclusion, our results were encouraging and suggest that the association of cytarabine, melphalan and TBI as a conditioning regimen for autologous SCT for AML on first remission appears to be safe and effective.

Different Responses to Arsenic Trioxide between NB4 and UF-1, Acute Promyelocytic Leukemia Cell Lines (급성 전골수성 백혈병 세포주간의 삼산화비소에 대한 반응)

  • Kim, Hye-Ran;Choi, Yoon-Jeong;Ryu, Seong-Yeoll;Lee, Young-Seok;Lee, Sang-Hwa
    • Journal of Life Science
    • /
    • v.16 no.5
    • /
    • pp.759-766
    • /
    • 2006
  • Acute promyelocytic leukemia (APL) is a myeloid leukemia caused by over-expression of fusion protein, PML/RAR$({\alpha})$, which was the result of chromosomal translocation and induces the blockage of differentiation of affected promyelocytes. Pharmacological dose of retinoic acid induces the activation of and subsequent degradation of PML/RAR$({\alpha})$ fusion protein, and then APL cells undergo through the normal differentiation pathway. Arsenic trioxide has proved effective in causing remission of acute promyelocytic leukemia by inducing apoptosis of this tumor cells, whereas the heterogeneity of cellular susceptibility to this cytotoxic agent limited its usage on more types of tumors in clinic. This work showed that arsenic trioxide could induce apoptosis of a panel of acute promyelocytic leukemic cell lines, all-trans-retinoic acid (ATRA) sensitive NB4 cells and ATRA resistant UF-1 cell. They were investigated with regard to the correlation between the inherent or intrinsic cellular level of GSH and the apoptotic susceptibility of the cells to arsenic trioxide. We manifested, in two cell types, the inherently existed difference in intracellular GSH level reactive to the arsenic trioxide, and a positive correlation between the GSH level and their apoptotic sensitivity to arsenic trioxide. And it showed that arsenic trioxide could differentiate promyelocytic cancer cells to the cells possessed of dendritic cell surface markers. Unravelling the cause of the different susceptibility between leukemic cells and proving that promyelocyte could be differentiated to dendritic cells by arsenic trioxide will help not only to understand the mechanism underlying the complete remission of acute promyelocytic leukemia induced by arsenic trioxide, but also to expand its clinical usage.

Bilateral Nephromegaly as a Presenting Symptom of Acute Lymphoblastic Leukemia (양측 신장비대로 진단된 급성림프구성 백혈병 1례)

  • Kim, Jong-Ho;Park, Jee-Min;Jung, Hyun-Joo;Park, Jun-Eun;Pai, Ki-Soo
    • Childhood Kidney Diseases
    • /
    • v.13 no.2
    • /
    • pp.278-281
    • /
    • 2009
  • Bilateral renal enlargement is a very rare manifestation as the primary presenting feature of acute lymphoblastic leukemia. We are reporting an unusual clinical picture of a 9-month-old male patient diagnosed as precusor B-cell lymphoblastic leukemia, who showed bilateral nephromegaly without any hepatosplenomegaly at the time of initial presentation.

Survival Factors and Cytokines for Acute Leukemia Patients with Chemotherapy Compared with Bone Marrow Transplantation (급성 백혈병 환자의 생존요인 및 사이토카인 분석)

  • Park, Hun-Hee;Shin, Gi-Soo
    • Journal of Korean Biological Nursing Science
    • /
    • v.10 no.2
    • /
    • pp.170-175
    • /
    • 2008
  • Purpose: The purpose of this study was to predict treatment outcome of chemotherapy compared with and bone marrow transplantation in acute leukemia patients. Methods: We respectively reviewed the characteristics of subjects, cytokine, complete remission time and survival time of 111 patients with acute leukemia, admitted in St. Mary's hospital, between July 2007 and August 2008. Results: The complete remission rate with chemotherapy group was 70.8% and bone marrow transplantation group was 54.3% but without statistically significance. The prognostic factors related with survival is classification of acute leukemia and complete remission time. Conclusion: This study suggests a need for nursing research and nursing intervention for acute leukemia patients.

  • PDF

Large Vessel Vasculitis as an Initial Manifestation of Acute Myeloid Leukemia: A Case Report (대혈관 혈관염이 첫 번째 징후로 나타난 급성 골수성 백혈병: 증례 보고)

  • Gayoung Jeon;Dongjin Yang;Jongchang Jang; Jongwan Kang
    • Journal of the Korean Society of Radiology
    • /
    • v.83 no.4
    • /
    • pp.918-923
    • /
    • 2022
  • Large vessel vasculitis is characterized by chronic inflammation within the aortic wall and its major branches. The inflammation is considered to occur as a result of immune dysregulation. Hematologic malignancy is one of the rare causes of secondary vasculitis. Herein, we report a rare case of large vessel vasculitis associated with acute myeloid leukemia mimicking primary vasculitis.

Neutropenia & Nutritional status during Chemotherapeutic cycle in Acute Myeloid Leukemia (급성골수성백혈병환자의 항암화학요법 주기내의 호중구감소증과 영양상태)

  • Kim, Myung-Hee;Kang, In-Soon;Jo, Ho-Yoon
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.10 no.2
    • /
    • pp.438-446
    • /
    • 2009
  • This study aims to investigate chemotherapy-induced neutropenia, nutritional status and both relation of patients with acute myeloid leukemia during 1st consolidation chemotherapy and the therapy-related cytopenic phase in order to determine more effective nutritional support. We review medical records of total 54 cases received first consolidation chemotherapy on P hospital in Busan. The duration of neutropenia(Absolute Neutrophil Count<$1000/{\mu}{\ell}$) is mean 14.78 days, neutropenia occur on mean 10th(9.54) day of chemotherapy(D10). The nutritional parameters of total protein, body weight, BMI showed no significant interval change during chemotherapeutic cycle except albumin, cholesterol. The neutropenia wasn't dependent on general factor of gender, age, comorbidities, Body Surface Area(BSA). The correlation wasn't revealed between neutropenia and nutritional status. In conclusion, although nutritional status didn't affect neutropenia, this study provides detailed information on the neutropenic response of acute myeloid leukemia patients during induction chemotherapy.